These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Herpes virus infections, HIV, and disease progression. Wait and see. Japour A AIDS Clin Care; 1995 Feb; 7(2):15, 18. PubMed ID: 12212540 [No Abstract] [Full Text] [Related]
44. Type I Interferons: Distinct Biological Activities and Current Applications for Viral Infection. Li SF; Gong MJ; Zhao FR; Shao JJ; Xie YL; Zhang YG; Chang HY Cell Physiol Biochem; 2018; 51(5):2377-2396. PubMed ID: 30537741 [TBL] [Abstract][Full Text] [Related]
45. Latency and acquired resistance--problems in chemotherapy of herpes infections. Darby G; Field HJ Pharmacol Ther; 1983; 23(2):217-51. PubMed ID: 6322214 [No Abstract] [Full Text] [Related]
46. [New antiviral agents in chronic viral hepatitis]. Gómez Cedenilla A; Zapater Hernández P; García Buey L; Abad Santos F; García Monzón C; González Mateos F; Moreno Otero R Rev Clin Esp; 1998 Feb; 198(2):104-13. PubMed ID: 9558926 [No Abstract] [Full Text] [Related]
47. Antivirals against DNA viruses (hepatitis B and the herpes viruses). Hewlett G; Hallenberger S; Rübsamen-Waigmann H Curr Opin Pharmacol; 2004 Oct; 4(5):453-64. PubMed ID: 15351349 [TBL] [Abstract][Full Text] [Related]
48. Fulminant varicella hepatitis in a human immunodeficiency virus infected patient: case report and review of the literature. Lechiche C; Le Moing V; François Perrigault P; Reynes J Scand J Infect Dis; 2006; 38(10):929-31. PubMed ID: 17008242 [TBL] [Abstract][Full Text] [Related]
49. Antiviral drug resistance. Pillay D; Geddes AM BMJ; 1996 Aug; 313(7056):503-4. PubMed ID: 8789961 [No Abstract] [Full Text] [Related]
51. Some aspects of the chemotherapy of herpes virus infections. Cohen SS Adv Pathobiol; 1976; (5):173-6. PubMed ID: 220854 [No Abstract] [Full Text] [Related]
52. Antiviral hepatitis and antiretroviral drug interactions. Perronne C J Hepatol; 2006; 44(1 Suppl):S119-25. PubMed ID: 16360231 [TBL] [Abstract][Full Text] [Related]
53. Novel approaches and challenges to treatment of central nervous system viral infections. Nath A; Tyler KL Ann Neurol; 2013 Sep; 74(3):412-22. PubMed ID: 23913580 [TBL] [Abstract][Full Text] [Related]
54. [Recommendations of Gesida/PNS/AEEH for the management and treatment of the adult patient co-infected with HIV and hepatitis A, B and C virus]. Panel de expertos de Gesida, Secretaría del Plan Nacional sobre el Sida (SPNS) y Asociación Española para el Estudio del Hígado (AEEH) Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):31.e1-31. PubMed ID: 20116629 [TBL] [Abstract][Full Text] [Related]
56. Ganciclovir resistance: a matter of time and titre. Drew WL Lancet; 2000 Aug; 356(9230):609-10. PubMed ID: 10968428 [No Abstract] [Full Text] [Related]
57. Established and emerging therapies for the treatment of viral hepatitis. Forton D; Karayiannis P Dig Dis; 2006; 24(1-2):160-73. PubMed ID: 16699274 [TBL] [Abstract][Full Text] [Related]
58. Perspectives on antiviral drug development. Wainberg MA Antiviral Res; 2009 Jan; 81(1):1-5. PubMed ID: 18948140 [TBL] [Abstract][Full Text] [Related]
59. Antiviral drug development: the road less taken. Balfour HH Ann Pharmacother; 1996 Sep; 30(9):964-6. PubMed ID: 8876857 [No Abstract] [Full Text] [Related]
60. Antiviral therapy in the chronic viral hepatitides. Mutimer D QJM; 1998 Sep; 91(9):593-6. PubMed ID: 10024912 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]